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OBJECTIVE — Thepurposeofthisstudywastocompareeffectsofinsulindetemironcedaily
versus twice a day in a basal-bolus insulin regimen.
RESEARCH DESIGN AND METHODS — In this open-label, 7-month study, 520
patientswithtype1diabeteswererandomlyassignedtoreceivedetemironcedailyortwicedaily
with mealtime insulin aspart. Insulin doses were titrated over 1 month, with patients followed
up over the subsequent 3 months. Thereafter, patients were able to switch from one regimen to
the other, with an additional nonrandomized 3-month follow-up, to a total of 7 months. The
primary end point was A1C at 4 months, with noninferiority deﬁned as a difference 0.4%
between groups.
RESULTS — A1C at 4 months was 8.1  0.9 versus 8.0  1.0% with once- and twice-daily
detemir, respectively, with an adjusted between-group difference of 0.12% (95% CI 0.01 to
0.25%), showing noninferiority for once-daily dosing. Similar results were found in the per
protocol population. Improvement in A1C was similar in both groups (0.4  0.8 vs. 0.5 
0.8%; P  0.09, NS) but with differences in the 7-point glucose proﬁle. Detemir doses were
lower (29  18 vs. 39  20 units/day, P  0.001), but aspart doses were higher (34  17 vs.
26  14 IU/day, P  0.001) with once-daily detemir. At 7 months, A1C decreased slightly in
patients switched from once-daily to twice-daily administration (8.2  0.8 vs. 8.0  0.8%; P 
0.34,NS)inassociationwithincreasedtotalinsulindoses(P0.05),butA1Cincreasedinthose
switched from twice-daily to once-daily administration (7.2  0.9 vs. 7.6  0.8%, P  0.05) in
association with decreased doses (P  0.05).
CONCLUSIONS — Although some individuals may beneﬁt from twice-daily dosing, the
most suitable routine starting schedule for detemir in a basal-bolus regimen for type 1 diabetes
is once-daily injection.
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T
he basal insulin analog insulin det-
emir (detemir) differs from human
insulin by a single amino acid dele-
tion and the acylation of myristic acid to
the B terminus of the molecule. These
changes affect the pharmacokinetics of
the insulin, prolonging absorption from a
subcutaneous depot through a unique
mechanism involving self-association of
detemir molecules and reversible binding
to albumin (1). The result is a more pro-
longed, less peaked absorption (and
hence pharmacodynamic) proﬁle com-
paredwiththatofNPHinsulin(NPH)(2).
Another property of detemir, believed to
result from albumin binding, is reduced
intrasubject variability of the pharmaco-
dynamic proﬁle (3) compared with those
of both NPH (4,5) and insulin glargine
(4,6). In theory, reduced intrasubject
variabilityshouldreducetheriskofhypo-
glycemia (4,7). This theory was con-
ﬁrmed clinically in comparative trials
against NPH involving basal-bolus ther-
apy in type 1 diabetes in which detemir
demonstrated similar efﬁcacy but consis-
tent reductions in the frequency of hypo-
glycemia during the night, when the
absence of mealtime bolus insulin un-
masks differences in the pharmacody-
namics of basal insulins (8). Detemir
has also been consistently associated
with reduced weight gain compared
with NPH (9).
Most initial studies of detemir in type
1diabetesinvolvedatwice-dailyregimen,
butrecentpharmacologicalanalyses(6,7)
suggest that detemir has a pharmacody-
namic proﬁle similar to that of insulin
glargine, a basal insulin that is routinely
injected once daily. Using a standard def-
inition for duration of action, detemir has
been reported to endure for a mean of
closeto24hintype1diabetesandlonger
in type 2 diabetes (7). In addition, data
from the large-scale observational Pre-
dictable Results and Experience in Diabe-
testhroughIntensiﬁcationandControlto
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uation (PREDICTIVE) study show that a
majority of patients have been using det-
emir once daily and achieving clinically
important improvements in glycemic
control(10),althoughthiswasnotacom-
parative trial. A recent analysis of basal
insulin studies by DeVries et al. (11) sug-
gested that, although a percentage of pa-
tients may beneﬁt from twice-daily basal
insulin dosing, the routine use of twice-
daily basal regimens tends to drive up the
total unit dose of insulin without corre-
spondinggainsinglycemiccontrol.These
observationscallintoquestiontheroutine
of twice-daily dosing of detemir in most
patients.Thepresentstudyistheﬁrstspe-
ciﬁcally designed to assess whether rou-
tine use of twice-daily detemir in basal-
bolus therapy for type 1 diabetes offers
any clinical advantages over once-daily
administration.
RESEARCH DESIGN AND
METHODS— The Assessment of De-
temir Administration in a Progressive
Treat-to-Target Trial (ADAPT) was an
open-label study performed at centers in
Belgium (6) and France (193). It com-
prised a randomized 4-month, parallel-
group period comparing once-daily with
twice-daily detemir, followed by a non-
randomized 3-month extension period
at the beginning of which crossover was
permitted.
Included were patients with type 1
diabetes diagnosed for 1 year and with
A1C 7.5–10%, regardless of their pre-
study insulin regimen. Exclusion criteria
included likelihood of pregnancy, use of
oral antidiabetes drugs, hypoglycemia
unawareness, severe degenerative com-
plications or associated disease, and asso-
ciated drugs or conditions capable of
altering glucose control. Withdrawal cri-
teria included serious adverse events,
pregnancy, the necessity of stopping
study treatment, and major protocol de-
viation as judged by a study committee.
For the randomized part of the study,
patients were assigned to either once-
daily (at bedtime) or twice-daily (before
breakfastandatbedtime)injectionsofde-
temir, with bolus doses of insulin aspart
(aspart) given three times daily at meal-
times. The randomization list was gener-
ated by computer using an aleatory
function before the start of the trial and
the Interactive Voice Response telephone
randomizationsystem.Bothinsulinswere
supplied in 100 units/ml 3-ml FlexPen
devices (Novo Nordisk, Copenhagen,
Denmark).
After 1 month of intensive titration,
patients were followed up over 3 more
months, with primary end points being
evaluatedattheendofthisperiod.Dosing
guidelines were developed to facilitate ti-
tration and switching patients to the new
insulin regimen from previous insulin
therapy. Initial doses of detemir were to
equal previous basal insulin doses, either
injected at bedtime (once-daily group) or
halfbeforebreakfastandhalfatbedtime
(twice-daily group). The initial dose of
mealtime aspart was to equal the meal-
time insulin doses used previously. If
3 mealtime injections were given pre-
viously, the new injections were begun
at 4 IU.
Subsequent titration was at the dis-
cretion of investigators and patients, but
guidelines were provided: detemir doses
were to be titrated against fasting glucose
valuesintheonce-dailygroupandagainst
fasting and predinner glucose values in
the twice-daily group. Detemir was to be
increased by 6 units if the mean glucose
concentration at these times over the 3
preceding days was 180 mg/dl, by 4
unitsif180–165mg/dl,by3unitsif165–
145mg/dl,andby2unitsif145–120mg/
dl. Detemir was decreased by 4 units if
unexplained glucose values 50 mg/dl
were observed and by 2 units if values of
50–72 mg/dl were seen. Aspart was to be
increased by 6 IU if mean postprandial
glucose values over the 3 preceding days,
measured1–1.5haftermeals,were270
mg/dl, by 4 IU if 200–270 mg/dl, and by
2 IU if 180–200 mg/dl.
At the end of the 4-month random-
ized period, the basal dosing schedule
was allowed to be switched at the discre-
tion of investigators and patients, al-
though the following guidelines were
provided: switching from once-daily to
twice-daily detemir was advised if the
4-month A1C was 7.5% (the European
guideline target at the time of trial regis-
tration) or most predinner glucose val-
ues were 120 mg/dl. Switching from
twice-daily to once-daily detemir was
advisedonlywhenA1Cwas7.5%,the
fasting detemir dose was 6 units, and
most predinner glucose values were
120 mg/dl.
Visits were made at inclusion (base-
line) and at 4 and 7 months. Telephone
contact was made weekly during the ﬁrst
month and then at 7, 10, 19, and 22
weeks.
A1Cwasdeterminedcentrally(Focus
Bio-Inova Europe) by high-performance
liquid chromatography (Bio-Rad Variant
II kit). Self-measurement of blood glu-
cose,forconstructionof7-pointglycemic
proﬁles, was requested to be made before
and after (1–1.5 h) meals and at bedtime
foreachofthe14daysbeforethe4-month
follow-up period.
Hypoglycemic episodes were classi-
ﬁed as “major” if assistance was required,
as“minor”ifbloodglucosereadings2.8
mmol/l (0.5 g/l) were recorded but pa-
tients were able to deal with the episodes
themselves, or as “symptoms only” if hy-
poglycemic symptoms were reported
without a conﬁrmed blood glucose mea-
surement. Hypoglycemia was docu-
mented over 24 h, and incidences of
hypoglycemia were based on events re-
corded in the last 14 days before each
main visit.
Statistical analyses
The primary end point was A1C at 4
months, with a noninferiority analysis
performed using ANCOVA adjusted for
baseline. Noninferiority was deﬁned be-
fore the study using the criterion agreed
on between Novo Nordisk and the U.S.
Food and Drug Administration (FDA) for
the detemir phase 3 study program,
namely, a difference in A1C between
groups of 0.4% A1C (12).
Secondary end points were analyzed
withANOVA,ANCOVA,ortheWilcoxon
test for quantitative variables and a 
2 or
Fisher’s exact test for qualitative ones.
SAS software (version 8.2; SAS Institute,
Cary, NC) was used. Analyses were per-
formed using the last observation carried
forwardmethod.Unlessotherwisestated,
results are shown as means  SD or per-
cent. Insulin dose data are presented as
total units, but similar results were found
using units per kilogram.
Because the extension period (4–7
months) was uncontrolled with unequal
cohort numbers, results at 7 months are
presented without statistical analyses be-
tween groups. Within-subject compari-
sons (4 vs. 7 months) are presented for
clinical interest in real-life situations but
should be considered with caution.
RESULTS
Disposition
A total of 520 patients were included and
randomly assigned, of whom 8 did not
take treatment; hence, the intent-to-treat
population included 512 patients (250
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detemir). Major protocol deviations were
observed in 29 and 26 patients taking
once-dailydetemir(12%)andtwice-daily
detemir (10%), respectively (P  0.34,
NS). The most common deviations were
no respect for randomization (16 pa-
tients; 3.1%), delayed baseline A1C assay
(14 patients; 2.7%), and A1C outside the
inclusion range (4 patients; 0.8%). Five
patients (1.0%) randomly assigned to
once-daily detemir switched without
consultation to twice-daily detemir.
Twenty-three patients withdrew from the
trial because of poor glycemic control (10
vs. 5 taking once-daily vs. twice-daily de-
temir, respectively, P  0.05) or discom-
fort (2 taking once-daily vs. 6 taking
twice-daily detemir, respectively, P 
0.05). All patients with major protocol
deviations were excluded from the per
protocol population.
Demographics
At inclusion, there were no between-
treatment differences between the once-
daily and twice-daily detemir groups
regarding sex (53 vs. 52% men, respec-
tively, P  0.74, NS), age (41  13 vs.
42  13 years, P  0.32, NS), BMI (25 
4 vs. 25  4 kg/m
2, P  0.08, NS), dura-
tion of diabetes (16  10 vs. 17  10
years, P  0.40, NS), frequency of degen-
erative complications (40 vs. 44%, P 
0.41, NS), previous insulin doses (52 
20 vs. 51  19 IU/day, P  0.79, NS),
number and type of insulin injections
(two or three injections 17 vs. 16%, me-
dianfourinjections70vs.72%,ﬁveorsix
injections13vs.12%,P0.88,NS),A1C
(8.50.8vs.8.51.0%,P0.71,NS),
and hypoglycemia frequency during the
preceding 2 weeks (3.3  3.6 vs. 3.6 
4.0, P  0.60, NS). Associated diseases
were less frequent in the once-daily det-
emir group (54 vs. 64%, P  0.05) be-
cause of a lower frequency of treated
hypothyroidism(2.4vs.5.4%,P0.05).
After randomization, suggested total
insulin doses proposed by the investiga-
tors were similar in the once-daily and
twice-daily detemir groups (respectively,
detemir 27  12 vs. 27  12 units/day,
P0.46,NS;aspart2512vs.2312
IU/day, P  0.64, NS). Twice-daily det-
emir was injected at a similar dose be-
fore breakfast and at bedtime (14  6
and 14  6 units/day, P  0.92, NS).
Aspart doses were slightly higher with
once-daily detemir (breakfast 7  4 vs.
7  4 IU/day, P  0.06, NS; lunch 9 
4vs.84IU/day,P0.05;dinner9
5 vs. 9  5 IU/day, P  0.11, NS).
Clinical outcomes
A1C data are summarized in Fig. 1. At 4
months, A1C was similar in the once-
daily and twice-daily groups (8.1  0.9
vs. 8.0  1.0%), with an adjusted
between-group difference of 0.12%
(95% CI –0.01 to 0.25; post hoc power
95%), thereby showing noninferiority
for once-daily dosing. Similar results
were found in the per protocol popula-
tion (adjusted difference 0.13%, 95%
CI–0.01to0.26;power92%).A1Cwas
7.0% in 14.2% of patients taking
once-daily detemir and 15.6% of pa-
tients taking twice-daily detemir (P 
0.67, NS). Improvement of A1C was
similar in both groups (0.4  0.8 vs.
0.5  0.8%; P  0.09, NS). At 4
months, capillary blood glucose levels
were lower with once-daily detemir be-
fore breakfast (P  0.0001) but higher
before and after other meals (P  0.02)
(Fig. 2).
There was a slight change in BMI with
both once-daily and twice-daily detemir
(0.2  0.8 vs. 0.2  1.0 kg/m
2, P  0.83,
NS). The frequency of hypoglycemia over
the 4-month randomization period was
similarinbothgroups(2116vs.2424
events per patient per 14 days, P  0.47,
NS) and did not differ by classiﬁcation of
severity. No differences were seen in the
pattern of other adverse events by group.
Both regimens were well tolerated, with
most adverse events not considered to be
related to the study drugs.
Insulin dose
Total insulin doses were similar with
once-daily and twice-daily detemir (62 
31 vs. 64  29 units/day, respectively,
P  0.34, NS), but detemir doses were
lowerwithonce-dailydosing(2918vs.
Figure 1—A: A1C values at baseline and at 4 and 7 months according to the original random-
ization group. F, patients originally randomized to once-daily detemir; f, patients originally
randomized to twice-daily detemir. B: A1C values at baseline and at 4 and 7 months according to
the original and ﬁnal basal dosing frequency. Error bars show SD. E, patients staying on once-
dailydetemirafter4months;F,patientsswitchingfromonce-totwice-dailydetemirat4months;
 , patients staying on twice-daily detemir after 4 months; f, patients switching from twice- to
once-daily detemir at 4 months.
Once- versus twice-daily insulin detemir
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versely, aspart doses were higher with
once-daily detemir (34  17 vs. 26  14
IU/day, P  0.001 [breakfast 9  6 vs.
7  5, P  0.01; lunch 11  6 vs. 8  4,
P0.001;dinner147vs.117,P
0.001]).
Nonrandomized 4- to 7-month
follow-up
After the 4-month randomized period,
mostpatientscontinuedinthestudywith
twice-daily detemir (172 from the once-
daily group and 226 from the twice-daily
group),with33patients(13%)remaining
with once-daily detemir and 10 (4%)
switching from twice-daily to once-daily
detemir.Nodifferencesinbaselinedemo-
graphics or disease characteristics were
detected between patients staying with
once-daily detemir or switching to twice-
daily detemir or between patients staying
with twice-daily detemir or switching to
once-dailydetemir.A1Cvaluesat4and7
months by actual detemir regimen are
shown in Fig. 1B. In patients staying with
once-daily detemir, A1C was 7.2  0.9%
at 4 months, remaining steady until 7
months at 7.4  0.9% (P  0.18, NS,
before versus after switching). For pa-
tients switching from once-daily to twice-
daily detemir, A1C was 8.2  0.8 and
8.0  0.8%, respectively, at 4 and 7
months(P0.34,NS,beforeversusafter
switching). A1C remained steady be-
tween4and7monthsinpatientsremain-
ing with twice-daily detemir (8.0  1.0
and 8.0  1.1%, P  0.89), but for those
switching from twice-daily to once-daily
detemir,A1Cincreasedfrom7.20.9to
7.6  0.8% (P  0.05, before versus after
switching, respectively).
Insulin dose data at 4 and 7 months
are presented by actual basal insulin reg-
imen in Fig. 3. There were very slight in-
creases in total insulin dose among
patientsremainingwiththeiroriginalreg-
imens (once-daily P  0.76, NS; twice
daily P  0.64, NS), a small increase in
patients switching from once-daily to
twice-daily detemir (P  0.05), and a
marked decrease in patients switching
from twice-daily to once-daily detemir
(P  0.05).
CONCLUSIONS— Most previous
clinical trials of detemir given in basal-
bolus therapy for type 1 diabetes used a
twice-daily dosing schedule. One study
allowed once- or twice-daily dosing (13),
andanotherusedonlyonce-dailydetemir
dosing but with regular human insulin
given instead of a rapid-acting analog at
mealtimes (14). The use of once-daily de-
temir in basal-bolus therapy is therefore
not well documented by trial data; yet,
pharmacodynamic evidence suggests
suitability for this more convenient
schedule (7).
This is the ﬁrst study to compare
once-daily and twice-daily regimens of
detemir as the basal component of basal-
bolus therapy in a randomized trial de-
sign. The patients studied were adults
with type 1 diabetes, diagnosed for 1
year, i.e., with little or no endogenous in-
sulin secretion, making this a valid test
system for differences in clinical end
points attributable to differences in basal
insulin regimen. Furthermore, baseline
glycemic control of patients was poor de-
spite the fact that the great majority were
using basal-bolus therapy; hence, the co-
hort can be regarded as a stringent one in
whichtoevaluateonce-dailydetemirdos-
ing. The 4-month results suggest that, on
average,atwice-dailydosingschedulehas
no clinically signiﬁcant advantage over
once-daily dosing. Mean A1C (Fig. 1A)
and the percentage of patients reaching
A1C 7.0% were not signiﬁcantly differ-
ent between dosing groups at this time,
whereas basal and (to a lesser extent)
overall insulin doses were shifted upward
with twice-daily dosing, consistent with
the observations of DeVries et al. (11).
This dose-shifting effect was also appar-
ent upon switching from once-daily to
twice-dailydetemir(Fig.3).Ourrandom-
ized 4-month data therefore suggest that
routine use of detemir in a twice-daily
regimen is unnecessary: once-daily det-
emir should be regarded as the routine
standard regimen.
Figure 2—Capillary glucose proﬁles at 4 months in once-daily (OD) and twice-daily (BID)
detemir groups. Mean glucose levels are shown, with error bars representing SD.
Figure 3—Detemir and aspart doses after 4 and 7 months in four groups of patients. Signiﬁcant
changesoftotalinsulindoses(4vs.7months;P0.05)wereobservedforpatientsswitchingfrom
once-daily (OD) to twice-daily (BID) and from twice daily to once-daily detemir. Signiﬁcance
represents the change in total insulin dose.  , total aspart; u, detemir at breakfast; f, detemir at
bedtime. d, day.
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therewasasmallexcessofnoncompleters
because of poor efﬁcacy in the once-daily
group and that differences were detected
in mean diurnal blood glucose proﬁles at
4months(Fig.2),withglucosetendingto
be lower before breakfast but rising to
higher levels later in the day after once-
daily evening dosing. These observations
are again consistent with those described
by DeVries et al. (11) with regard to stud-
ies of insulin glargine (15–17). As these
glycemic proﬁles depict mean values, the
implication is that some individuals will
showamoreextremeriseinglucosewhen
treated with once-daily detemir, and it
might be better for such individuals to be
switched to twice-daily dosing. Again,
this scenario has been described previ-
ously in studies involving insulin glargine
(15,17,18).
When the 7-month follow-up data
are considered in terms of original
groups, there is little change (Fig. 1B),
supporting the view that once-daily dos-
ing is an appropriate routine starting reg-
imen for detemir. However, this trial was
not a randomized crossover study. The
glycemic criteria by which crossovers
wererecommendedbiasessubsequentre-
sults in favor of twice-daily dosing be-
cause poor responders to once-daily
dosing were encouraged to switch to
twice-dailydosing,whereasonlygoodre-
sponders to twice-daily dosing were en-
couraged to switch to once-daily dosing.
Evidence that this was indeed the case is
provided in Fig. 1B, where it is notewor-
thy that patients remaining with once-
daily dosing had a much lower 4-month
A1C than those switching to twice-daily
dosing. Conversely, patients switching
fromtwice-dailytoonce-dailydosinghad
a much lower 4-month A1C than those
remaining with once-daily dosing. Inter-
estingly, although there was a tendency
for A1C to decrease over months 4–7 in
patients switched from once-daily to
twice-daily dosing, the magnitude of
change was small and (at 0.2% A1C) be-
neaththeaprioricriterionagreedonwith
the FDA for clinical signiﬁcance. The pa-
tients with good glycemic control taking
twice-daily detemir who switched to
once-daily dosing at 4 months showed an
increase in A1C of a magnitude deemed
clinically signiﬁcant (0.4%, P  0.05).
Nevertheless,the7-monthA1Cinthisco-
hort (7.6%) was lower than that of pa-
tients who remained with twice-daily
dosing throughout and lower than that of
the cohort who switched from once-daily
to twice-daily dosing. It must also be
notedthattherewasamarkeddecreasein
total insulin dose in patients switching
from twice-daily to once-daily detemir,
withthemorningbasaldoseremovedand
the evening dose apparently not sufﬁ-
ciently increased to compensate (Fig. 3).
Taken altogether, these observations
again support once-daily dosing as an ef-
ﬁcient standard regimen for initiating de-
temir, although the slight reversal in
patients’ A1C after switching again sug-
gests the existence of a small subset of
patients who do beneﬁt from twice-daily
dosing.
A limitation of our study is the open-
label design, chosen to avoid a compli-
cated double-dummy injection schedule.
This design is likely to have inﬂuenced
the high frequency of switching from
once-daily to twice-daily detemir at the
completion of the randomized phase. Af-
tertheopportunitytoswitchat4months,
28%ofpatientstakingonce-dailydetemir
had A1C 7.5%, yet only 13% elected to
stay with this regimen. It is likely that pa-
tients and investigators may have had the
preconception that a twice-daily regimen
would achieve better glycemic control;
however, switching from once-daily to
twice-daily dosing, on average, yielded
only marginal improvement. Arguably,
another limitation of our study is that the
data need to be viewed in the context of
glycemic control falling short of modern
guideline targets. Although guidelines
were given, titration was largely carried
outatthediscretionofpatientsandinves-
tigators; hence, this study cannot be con-
sideredatreat-to-targetstudy.Forinstance,
patientsswitchingfromtwice-dailytoonce-
dailydosingdidnottendtocompensatefor
theimmediatebasalinsulindosereduction.
However, the cohort studied were patients
withtype1diabeteswithpoorbaselinegly-
cemic control (A1C 8.5%), despite the use
of multiple-injection (four to six injections
per day) therapy, so mean improvement of
0.4–0.5%over4monthsmaynotfallshort
of realistic clinical expectations.
In summary, this study demonstrates
the overall noninferiority of once-daily
dosing based on a priori criteria when de-
temir is used in basal-bolus therapy for
type 1 diabetes. The data do, however,
also suggest the existence of a subset of
patientswhowillbeneﬁtfromtwice-daily
dosing, as has also been demonstrated in
studies of insulin glargine (15–17). Thus,
inindividualpatientsinwhomapoorover-
all response is seen with high predinner
blood glucose values, adding a second dose
of detemir, as is the case for all other basal
insulins, is worth considering. As a stan-
dard regimen, however, detemir should
be given once daily in the basal-bolus
therapy of patients with type 1 diabetes
because, on average, this leads to similar
A1C with reduced injection frequency.
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